Catalyst Pharma (CPRX) Plans to Continue Clinical Development of CPP-109
More News related to CPRX
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- Catalyst (CPRX) Announces Organizational Changes and CEO McEnany's Term Extension
- Hapoalim Securities Upgrades Catalyst Pharmaceutical (CPRX) to Hold
- Morning Movers 10/05: DEPO, AVII, OPTV, CRXX, UCTT, CPRX Higher; FOLD, FTBK, SGEN, SCLN, REED Lower
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company's decision was made after, and based upon, an in-depth review of the results obtained from its 186-patient Phase II clinical trial evaluating the use of CPP-109 for the treatment of cocaine addiction (CPP-01004) and the top-line results obtained from its 57-patient proof-of-concept study evaluating the use of CPP-109 for the treatment of methamphetamine addiction (CPP-02001). Catalyst's decision to continue the development of the drug for both indications was supported by a panel of experts who recently met and agreed with the Company's conclusion that there was sufficient evidence of safety and efficacy to justify further development of CPP-109, based upon these trial data and previously published studies of vigabatrin to treat addiction.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
